POLATUZUMAB VEDOTIN COMBINED WITH ORELABRUTINIB AND RITUXIMAB (PRO REGIMEN) AS FRONTLINE THERAPY IN VERY ELDERLY AND FRAIL PATIENTS WITH DLBCL: UPDATED RESULTS FROM A PHASE II STUDY

EHA Library, wenyu shi, 4208623

EXTRANODAL INVOLVEMENT AND SITE-SPECIFIC SURVIVAL IN EARLY-STAGE DIFFUSE LARGE B-CELL LYMPHOMA: A POPULATION-BASED STUDY

EHA Library, Antonios Balantinakis, 4208624

REAL-WORLD OUTCOMES OF GLOFITAMAB PLUS GEMCITABINE AND OXALIPLATIN  IN RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA: A EUROPEAN MULTICENTER COHORT

EHA Library, Thomas Melchardt, 4208625

FIXED-DURATION SUBCUTANEOUS MOSUNETUZUMAB IN ELDERLY/UNFIT PATIENTS WITH PREVIOUSLY UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA: PHASE 2 MORNINGSUN STUDY INTERIM ANALYSIS AND PATIENT-REPORTED OUTCOMES

EHA Library, John M. Burke, 4208627

RISK FOR CYTOKINE RELEASE SYNDROME IN PATIENTS WITH LARGE B-CELL LYMPHOMA TREATED WITH CD3XCD20 BISPECIFIC ANTIBODIES: AN INTERNATIONAL MULTICENTER RETROSPECTIVE STUDY

EHA Library, Giuseppe Gritti, 4208628

DYNAMIC CHANGES IN MONONUCLEOSOMAL CFDNA PROFILES IDENTIFY HIGH-RISK PATIENTS WITH LARGE B-CELL LYMPHOMA

EHA Library, Amos Bonsdorff, 4208630

LONGITUDINAL SAFETY OF LISOCABTAGENE MARALEUCEL (LISO-CEL) IN PATIENTS WITH SECOND-LINE (2L) OR LATER (2L+) LARGE B-CELL LYMPHOMA (LBCL)

EHA Library, Stephan Mielke, 4208632

FIXED-DURATION EPCORITAMAB MONOTHERAPY INDUCES HIGH RESPONSE AND MRD-NEGATIVITY RATES IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED LARGE B-CELL LYMPHOMA AND COMORBIDITIES: RESULTS FROM EPCORE DLBCL-3

EHA Library, Umberto Vitolo, 4208633

IMMUNE RECONSTITUTION AFTER CD19-DIRECTED CAR-T THERAPY IN B-CELL NON-HODGKIN LYMPHOMA: PROGNOSTIC IMPACT, PRODUCT-SPECIFIC PATTERNS, AND ASSOCIATIONS WITH CAR-T PERSISTENCE AND SUBSETS

EHA Library, Yu Yagi, 4208634

EPCORITAMAB IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R/R DLBCL): INSIGHTS FROM THE REAL-WORLD EPCORITAMAB PATIENT CHARACTERISTICS AND OUTCOMES RESEARCH (REAL-EPCOR) STUDY

EHA Library, Yumeng Zhang, 4208637

IDENTIFICATION OF AN OPTIMAL ABSOLUTE LYMPHOCYTE COUNT BEFORE BISPECIFIC ANTIBODY THERAPY FOR LARGE B-CELL LYMPHOMAS: A COLLABORATIVE U.S. BISPECIFIC CONSORTIUM (CUBIC) STUDY

EHA Library, Zachary Hunzeker, 4208638

EFFECTIVENESS AND SAFETY OF CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY AFTER TAFASITAMAB (TAFA) IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (R/R DLBCL): A REAL-WORLD STUDY

EHA Library, Mariana Bastos-Oreiro, 4208640

REAL-WORLD EFFICACY AND SAFETY OF POLATUZUMAB VEDOTIN WITH R-CHP IN PREVIOUSLY UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA: A UK MULTI-CENTRE STUDY

EHA Library, James Paterson, 4208642

FIRST-LINE SELINEXOR IN COMBINATION WITH R-CHOP FOR EBV-POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA (XPLORE): A SINGLE-ARM, PHASE IB/II TRIAL

EHA Library, Qingqing Cai, 4208644

HIGH DOSES OF METHOTREXATE AND CYTARABINE WITH OR WITHOUT INTRAVITREAL METHOTREXATE INJECTIONS IN A COHORT OF 31 HIV-NEGATIVE PATIENTS WITH PRIMARY VITREORETINAL LYMPHOMA

EHA Library, Teresa Calimeri, 4208645

REAL‑WORLD TREATMENT PATTERNS AND OUTCOMES OF FIRST-LINE (1L) TREATMENTS IN PATIENTS WITH NEWLY DIAGNOSED DIFFUSE LARGE B‑CELL LYMPHOMA (DLBCL) IN THE UNITED STATES (US) COMMUNITY ONCOLOGY SETTING

EHA Library, David J. Andorsky, 4208646

TREATMENT FOR MALIGNANT LYMPHOMAS AND RISK OF THERAPY-RELATED MYELOID NEOPLASMS OVERALL AND WITH HIGH-RISK FEATURES

EHA Library, Joel Joelsson, 4208647

IMPACT OF BASELINE NEUTROPHIL-TO-LYMPHOCYTE RATIO (NLR) ON SURVIVAL OUTCOMES IN PATIENTS WITH LYMPHOMA FOLLOWING BISPECIFIC ANTIBODY TREATMENT

EHA Library, Allison Bock, 4208649

LENGTH OF STAY, HEALTHCARE RESOURCE UTILIZATION (HCRU) AND REHOSPITALIZATION OF PATIENTS TREATED WITH AXI-CEL OR LISO-CEL FOR SECOND-LINE LARGE B-CELL LYMPHOMA (LBCL) IN FRANCE

EHA Library, Florian Colrat, 4208650

INCIDENCE AND OUTCOME OF RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA AND IMPLEMENTATION OF NOVEL T-CELL-ENGAGING THERAPIES IN A POPULATION-BASED SETTING

EHA Library, Sara Harrysson, 4208652

A REAL-WORLD COMPARISON OF CD3XCD20 BISPECIFIC ANTIBODY (BSAB) MONOTHERAPY VS BSAB COMBINATIONS IN RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA: A COLLABORATIVE US BISPECIFIC CONSORTIUM (CUBIC) STUDY

EHA Library, Karan Chohan, 4208653

CLINICAL CHARACTERISTICS AND EFFICACY OF MYC/BCL-2 DOUBLE-EXPRESSING DIFFUSE LARGE B-CELL LYMPHOMA: REAL-WORLD DATA FROM THE BELIEVE STUDY

EHA Library, Pengpeng Xu, 4208654

PHASE II STUDY OF LENALIDOMIDE MAINTENANCE AFTER RITUXIMAB-METHOTREXATE-BASED INDUCTION THERAPY IN PRIMARY CNS LYMPHOMA

EHA Library, Ji Yun Lee, 4208655

THE PHS W-INDEX: A NOVEL PROGNOSTIC FRAMEWORK INTEGRATING NUTRITIONAL AND HEMATOLOGICAL MARKERS TO PREDICT OUTCOMES IN DLBCL PATIENTS TREATED WITH GLOFITAMAB

EHA Library, Vít Procházka, 4208657

GLOFITAMAB IN RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA

EHA Library, Jiayin He, 4208661

SINGLE-TARGET (CD19) VERSUS DUAL-TARGET (CD19/CD22 OR CD19/CD20) CAR T-CELL THERAPY IN RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS

EHA Library, Ying He, 4208662

FOLLOW-UP-TIME–ADJUSTED NON-RELAPSE MORTALITY (NRM) IN PATIENTS WITH NON-HODGKIN LYMPHOMA FOLLOWING CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY WITHIN CLINICAL TRIALS

EHA Library, Michael Leisch, 4208663

SAFETY AND EFFICACY OF RELMACABTAGENE AUTOLEUCEL (RELMA-CEL) IN ADULT PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA：RESULTS FROM AN OPEN-LABEL, SINGLE-ARM STUDY

EHA Library, Xiangrui Meng, 4208664

EARLY SILTUXIMAB RESCUE FOR PERSISTENT CRS IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA RECEIVING AXICABTAGENE CILOLEUCEL: A REAL-WORLD EXPERIENCE

EHA Library, Adolfo Jesus Saez Marin, 4208665

PROGNOSTIC VALUE OF DEAUVILLE 5-POINT SCALE ASSESSED ON PET-CT FOLLOWING FIRST-LINE TREATMENT IN DLBCL: A RETROSPECTIVE STUDY

EHA Library, Henry Kouva, 4208667

IMPACT OF VINCRISTINE DOSE MODIFICATIONS OR SUBSTITUTION ON CLINICAL OUTCOMES IN R-CHOP TREATED PATIENTS WITH DLBCL

EHA Library, Paw Jensen, 4208669

EFFECTS OF ANTIBIOTIC-EXPOSURE AND LEVOFLOXACIN-PROPHYLAXIS ON OUTCOMES AFTER CART IN LARGE B-CELL LYMPHOMAS

EHA Library, Giulia Gabrielli, 4208670

AGE-INDEPENDENT OUTCOMES AND COMPETING RISK DYNAMICS IN RELAPSED/REFRACTORY LBCL: A REAL-WORLD ANALYSIS

EHA Library, Massimiliano Marinoni, 4208672

HIGH PROPORTION OF INTRATUMORAL TCF1+ T-CELLS PREDICTS FAVORABLE IMMUNOTHERAPY RESPONSE IN RELAPSED/REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA

EHA Library, Xia Zhao, 4208674

RESISTIN ASSOCIATES WITH POOR PROGNOSIS AND PROMOTES TUMOR GROWTH IN DIFFUSE LARGE B-CELL LYMPHOMA

EHA Library, wenyu shi, 4208675

BRUTON TYROSINE KINASE INHIBITOR MAINTENANCE THERAPY IN FIRST-LINE DIFFUSE LARGE B-CELL LYMPHOMA: A MULTICENTER REAL-WORLD STUDY CHALLENGING CONVENTIONAL PARADIGMS

EHA Library, Na Yao, 4208678

GOLIDOCITINIB COMBINED WITH CHOP IN NEWLY-DIAGNOSED PERIPHERAL T-CELL LYMPHOMA: PRELIMINARY RESULTS FROM A PHASE 1/2 CLINICAL TRIAL(JACKPOT 53)

EHA Library, Chong Wei, 4208680

ANTI-PD-1-ANTIBODY (TISLELIZUMAB) PLUS CHIDAMIDE, LENALIDOMIDE AND ETOPOSIDE FOR REFRACTORY/RELAPSED EXTRANODAL NK/T-CELL LYMPHOMA, NASAL TYPE : A PROSPECTIVE, MULTICENTER, SINGLE-ARM TRIAL

EHA Library, Yu Chang, 4208682

REAL-WORLD INSIGHTS INTO CLINICAL FEATURES AND OUTCOMES IN EXTRANODAL T-CELL LYMPHOMAS: RESULTS FROM THE INTERNATIONAL T-CELL PROJECT 2.0 PROSPECTIVE COHORT STUDY.

EHA Library, Maryna Bushuieva, 4208683

LYMPHOMA-ASSOCIATED HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS: INCIDENCE, CLINICAL PHENOTYPE, AND OUTCOMES IN A GLOBAL DATABASE STUDY

EHA Library, Phyo Thazin Myint, 4208685

AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANTATION FOR PLASMABLASTIC LYMPHOMA: A STUDY FROM THE EBMT LYMPHOMA WORKING PARTY

EHA Library, Joseph Kauer, 4208687

AUTOLOGOUS BONE MARROW TRANSPLANTATION. INSIGHTS FROM INTERNATIONAL T-CELL PROJECT 2.0

EHA Library, Nazarii Shokun, 4208688

PHASE I STUDY OF TR115, A NOVEL SELECTIVE EZH2 INHIBITOR, IN RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA AND ADVANCED SOLID TUMORS

EHA Library, Juying Wei, 4208689

DIFFERENCES IN OUTCOMES FOR ELDERLY PATIENTS WITH DLBCL TREATED AT AMERICAN ACADEMIC VS COMMUNITY PROGRAMS: A 10-YEAR SURVIVAL ANALYSIS

EHA Library, Luis Villela, 4208693

PROGNOSTIC STRATIFICATION AND CLINICAL CHARACTERIZATION OF EPSTEIN-BARR VIRUS STATUS IN PERIPHERAL T-CELL LYMPHOMA: A RE-EVALUATION OF THE “LOW-RISK” PATIENT

EHA Library, Rong Wei, 4208699

HIGH PD-L1 EXPRESSION PREDICTS RELAPSE AND WORSE EVENT‑FREE SURVIVAL IN PEDIATRIC PATIENTS DIAGNOSED WITH ANAPLASTIC LARGE CELL LYMPHOMA: A RETROSPECTIVE STUDY OF 117 PATIENTS

EHA Library, Mariam Elsherif, 4208700

REAL-WORLD DURABLE CLINICAL BENEFITS OF TIRABRUTINIB AND ITS SAFETY PROFILE IN RELAPSED OR REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA: INTERIM ANALYSIS FROM THE REVEAL STUDY

EHA Library, Liang-Tsai Hsiao, 4208702

BRENTUXIMAB VEDOTIN WITH CHEMOTHERAPY IN FRONTLINE TREATMENT FOR CHINESE PATIENTS WITH CD30-POSITIVE PERIPHERAL T-CELL LYMPHOMA

EHA Library, Yuqin Song, 4208704

EXCEPTIONAL EFFICACY AND MANAGEABLE SAFETY OF GOLIDOCITINIB COMBINED WITH CHOP AS FIRST-LINE TREATMENT FOR PERIPHERAL T-CELL LYMPHOMA (JACKPOT52): PRELIMINARY RESULTS FROM A PHASE I/II STUDY

EHA Library, He Li, 4208703

PROVISIONAL PROGNOSTIC SCORE FOR HEPATOSPLENIC T-CELL LYMPHOMA

EHA Library, Philip Haddad, 4208701

CHARACTERIZING CASTLEMAN'S DISEASE IN GERMANY: INTERIM RESULTS FROM THE ABC-CD STUDY

EHA Library, Katharina Cron, 4208698

A NOVEL TRIPLET REGIMEN OF TISLELIZUMAB, GOLIDOCITINIB, AND SELINEXOR FOR RELAPSED/REFRACTORY EXTRANODAL NK/T-CELL LYMPHOMA: PRELIMINARY SAFETY AND EFFICACY FROM A PHASE IB/II STUDY

EHA Library, Rong Tao, 4208697

DETERMINANTS OF SURVIVAL IN AGGRESSIVE NK-CELL LEUKEMIA (ANKL): ANALYSIS OF AN UPDATED REAL-WORLD POOLED DATABASE

EHA Library, Philip Haddad, 4208696

RANDOMIZED PHASE 3 TRIAL OF WATCHFUL WAITING VERSUS INTERFERON-ALFA AND ZIDOVUDINE FOR INDOLENT ADULT T-CELL LEUKEMIA-LYMPHOMA: JCOG1111C

EHA Library, Kenji Ishitsuka, 4208695

TUMOR HETEROGENEITY DECIPHERING FOR INTERPRETABLE EARLY WARNING OF ADVERSE THERAPY RESPONSE IN EXTRANODAL NK/T-CELL LYMPHOMA

EHA Library, Chong Jiang, 4208694

RUXOLITINIB COMBINED WITH P-GEMOX IN ADULT PATIENTS WITH NEWLY DIAGNOSED AGGRESSIVE NATURAL KILLER CELL LEUKEMIA

EHA Library, Xueying Yang, 4208692

LINPERLISIB PLUS CHOP FOR NEWLY DIAGNOSED PERIPHERAL T-CELL LYMPHOMA: A SINGLE-ARM, PHASE IB/II STUDY (LINCH TRIAL)

EHA Library, Qingqing Cai, 4208691

ORELABRUTINIB PLUS R-CHOP FOR THE TREATMENT OF NEWLY DIAGNOSED NON-GCB DOUBLE-EXPRESSOR DIFFUSE LARGE B-CELL LYMPHOMA: A MULTICENTER, SINGLE-ARM, PHASE II STUDY

EHA Library, Yang Yang, 4208626

NUTRITIONAL PARAMETERS  AS PROGNOSTIC MARKERS IN OLDER PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA: A POST-HOC ANALYSIS OF THE ELDERLY PROJECT BY FONDAZIONE ITALIANA LINFOMI

EHA Library, Salvatrice Mancuso, 4208629

ALEMTUZUMAB EXPOSURE AND SUSTAINED IL-2 DRIVE UCART20X22 EXPANSION AND CLINICAL RESPONSE INADULTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA: NATHALI-01 STUDY

EHA Library, Emmanuel Bachy, 4208631

EFFICACY AND SAFETY OF TIRABRUTINIB FOR RELAPSED OR REFRACTORY SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA: RESULTS OF THE PHASE II CRYSTAL/NCCH2201 STUDY

EHA Library, Noriko Fukuhara, 4208635

INFECTION RATES IN PATIENTS TREATED WITH CAR-T VERSUS AUTOLOGOUS STEM CELL TRANSPLANT FOR RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA AND IN THE GENERAL POPULATION: A SWEDISH POPULATION-BASED STUDY

EHA Library, Kristina Noring, 4208636

ORELABRUTINIB, RITUXIMAB, AND THIOTEPA (ORT) IN COMBINATION WITH OR WITHOUT HIGH-DOSE METHOTREXATE IN UNTREATED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA

EHA Library, Chunmei Yang, 4208639

ORELABRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY PRIMARY OR SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA: A MULTICENTER, OPEN-LABEL, PHASE II STUDY

EHA Library, Lijuan Deng, 4208641

GLOFITAMAB MONOTHERAPY OR COMBINATION THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY PRIMARY OR SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA: A MULTICENTER RETROSPECTIVE STUDY

EHA Library, Lin Fu, 4208643

REAL-WORLD EFFICACY AND GENOMIC LANDSCAPE OF POLATUZUMA VEDOTIN-BASED FIRST-LINE THERAPY IN DIFFUSE LARGE B-CELL LYMPHOMA: A FOCUS ON TP53 MUTATIONS AND TREATMENT RESPONSE

EHA Library, Jia Liu, 4208648

OUTCOMES OF SECOND-LINE AXICABTAGENE CILOLEUCEL AND COMPARISON TO AUTOLOGOUS STEM CELL TRANSPLANTATION IN EARLY RELAPSED/PRIMARY REFRACTORY LARGE B-CELL LYMPHOMA PATIENTS

EHA Library, Lina Kolloch, 4208651

ESTABLISHMENT AND VALIDATION OF A PROGNOSTIC NOMOGRAM BASED ON THE PROGNOSTIC NUTRITIONAL INDEX FOR CAR-T THERAPY IN RELAPSED/REFRACTORY LYMPHOMA

EHA Library, Fan Yang, 4208656

PHASE 2 TRIAL OF GLOFITAMAB, POLATUZUMAB VEDOTIN AND ZANUBRUTINIB IN UNTREATED ELDERLY DLBCL PATIENTS: SAFETY RUN-IN RESULTS

EHA Library, Yuhong Ren, 4208658

EFFICACY AND SAFETY OF GLOFITAMAB IN RELAPSED/REFRACTORY B-CELL NON HODGKIN LYMPHOMA: RESULTS FROM THE RETROSPECTIVE OBSERVATIONAL GIMEMA-FIL IMM0123 STUDY

EHA Library, Anna Guidetti, 4208659

SERUM MIR-155-3P, MIR-142-3P AND MIR-22-3P AS DIAGNOSTIC AND PROGNOSTIC BIOMARKERS IN PATIENTS WITH LARGE B-CELL LYMPHOMA (LBCL): A SINGLE CENTER STUDY

EHA Library, Andreas-Epameinondas Koumpis, 4208660

EVALUATING THE CLINICAL OUTCOMES OF RIPERTAMAB IN NON-HODGKIN'S LYMPHOMA: AN OPEN-LABLE, MULTI-CENTER, PERSPECTIVE STUDY

EHA Library, Jun Ma, 4208666

OUTCOMES OF SECOND-LINE CAR-T THERAPY IN STARGLO-ELIGIBLE PATIENTS: A COMPARATIVE ANALYSIS

EHA Library, Gil Fridberg, 4208668

REAL-WORLD EFFICACY, SAFETY, AND MOLECULAR CHARACTERIZATION OF POLATUZUMAB VEDOTIN–BASED FIRST-LINE THERAPY IN DIFFUSE LARGE B-CELL LYMPHOMA: A SINGLE-CENTER STUDY WITH COMPREHENSIVE NGS PROFILING

EHA Library, Liang Wang, 4208671

PLASMA COPPER AS PROGNOSTIC BIOMARKER IN DIFFUSE LARGE B-CELL LYMPHOMA

EHA Library, Jinghan Wang, 4208673

CONTIGUOUS SPREAD, NOT HEMATOGENOUS DISSEMINATION: RETHINKING CNS RISK AND TREATMENT INTENSITY IN PRIMARY SINONASAL DLBCL—A 94-PATIENT REAL-WORLD EVIDENCE STUDY

EHA Library, Na Yao, 4208676

EVALUATION AND VALIDATION OF AUTOMATED MULTIPLEXED IMMUNOFLUORESCENCE FOR CLINICAL LYMPHOMA DIAGNOSES

EHA Library, Antonio Sorrentino, 4208677

MAPPING THE METHODOLOGY & ATTRIBUTES OF GLOBAL LYMPHOMA REGISTRIES: A LYMPHOMA REGISTRY ALLIANCE (LYRA) INITIATIVE

EHA Library, Eliza Chung, 4208679

EFFICACY AND SAFETY OF ORELABRUTINIB COMBINED WITH SINTILIMAB IN PATIENTS WITH RELAPSED/REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (R/R PCNSL): A PROSPECTIVE MULTICENTER PHASE II STUDY

EHA Library, Yan Zhang, 4208681

TEMPORAL TRENDS AND RISK FACTORS FOR TUBERCULOSIS IN LYMPHOMA PATIENTS: A SWEDISH POPULATION-BASED STUDY (2002–2024)

EHA Library, Torsten Dahlén, 4208684

OUTCOMES AND PROGNOSTIC RISK FACTORS IN NODAL PERIPHERAL T-CELL LYMPHOMA. RESULTS FROM THE INTERNATIONAL T-CELL PROJECT 2.0 PROSPECTIVE COHORT STUDY

EHA Library, Stefano Luminari, 4208686

INCIDENCE AND OUTCOMES OF BURKITT LYMPHOMA: AN ENGLAND-WIDE COHORT STUDY FROM THE UNCOVER STUDY GROUP

EHA Library, Matthew R. Wilson, 4208690

GVHD PROPHYLAXIS INCLUDING ATG REMAINS STANDARD OF CARE FOR HLA-COMPATIBLE UNRELATED DONOR HEMATOPOIETIC CELL TRANSPLANTATION: RESULTS FROM A LARGE RANDOMIZED CONTROLLED TRIAL COMPARING ATG AND PTCY

EHA Library, Johannes Schetelig, 4217020

FIRST-IN-CLASS SWITCHABLE ALLOGENEIC CAR-T THERAPY FOR CD123+ AML – RESULTS FROM THE PHASE IA REVSTAR-123 (AVC-201-01) STUDY

EHA Library, Martin Wermke, 4214974

FIRST-IN-HUMAN TRIAL OF LB2501, AN IN VIVO CD19/CD20 DUAL TARGETING CAR-T THERAPY, IN RELAPSED/REFRACTORY B-CELL NHL

EHA Library, Lei Fan, 4214973

BCMA CAR-T CELL THERAPY INDUCES COMPREHENSIVE IMMUNE RESETTING AND DURABLE REMISSION IN REFRACTORY PRIMARY IMMUNE THROMBOCYTOPENIA

EHA Library, Jinhui Shu, 4214970

FIXED-DURATION PIRTOBRUTINIB PLUS VENETOCLAX–RITUXIMAB VERSUS VENETOCLAX–RITUXIMAB FOR PATIENTS WITH PREVIOUSLY TREATED CLL/SLL: A PHASE 3, RANDOMIZED TRIAL (BRUIN CLL-322)

EHA Library, Faculty / Presenters, 4214968

TECLISTAMAB IMPROVES DEPTH OF RESPONSE AND PFS VERSUS LENALIDOMIDE-DEXAMETHASONE IN HIGH-RISK SMOLDERING MULTIPLE MYELOMA: RESULTS FROM THE PHASE 2 IMMUNOPRISM TRIAL

EHA Library, Omar Nadeem, 4214975

SELINEXOR PLUS RUXOLITINIB IN JANUS KINSE INHIBITOR–NAÏVE MYELOFIBROSIS: PHASE 3 SENTRY TRIAL

EHA Library, Claire HARRISON, 4214969

MEZIGDOMIDE, CARFILZOMIB, AND DEXAMETHASONE (MEZIKD) VS CARFILZOMIB AND DEXAMETHASONE (KD) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM THE PHASE 3 SUCCESSOR-2 TRIAL

EHA Library, Meletios Dimopoulos, 4214971

GILTERITINIB VERSUS MIDOSTAURIN IN PATIENTS WITH NEWLY DIAGNOSED FLT3-MUTATED ACUTE MYELOID LEUKEMIA ELIGIBLE FOR INTENSIVE THERAPY: RESULTS FROM THE PHASE 3 HOVON156/AMLSG28-18/PASHA TRIAL

EHA Library, Marc Raaijmakers, 4214972

TARGETING GPR183 REVERSES CHEMORESISTANCE AND SUPPRESSES LEUKEMIC PROGRESSION IN ACUTE MYELOID LEUKEMIA BY MODULATING GLYCOSPHINGOLIPID METABOLISM

EHA Library, Haihui Zhuang, 4209104

POTENTIAL IMPACT OF CD8+ T-CELL IL-2 EXPRESSION AND LACK OF T-SENESCENT EXPANSION ON BLINATUMOMAB MRD RESPONSE: LONGITUDINAL IMMUNE MONITORING IN ALL-B PATIENTS

EHA Library, Andrea Duminuco, 4209102

STIL-TAL1 DELETED T-ALLS TOLERATE STIL HAPLOSUFFICIENCY THROUGH A THERAPEUTICALLY EXPLOITABLE FBXW7 AXIS

EHA Library, Daisy Gresham, 4209099

NOVEL CD38-CD3 BISPECIFIC ANTIBODIES FOR IMMUNOTHERAPY OF ACUTE LEUKEMIA WITH T-CELL PHENOTYPE

EHA Library, Jianxiang Wang, 4209096

LEUKAEMOGENESIS IS INDUCED IN CYTOKINE DEPENDENT PARENTAL BA/F3 CELLS BY EXTRACELLULAR VESICLES FROM CYTOKINE INDEPENDENT CRLF2 P.F232C BA/F3 CELLS

EHA Library, Maxim Buckley, 4209097

PRMT7 OVEREXPRESSION PREDICTS POOR SURVIVAL IN B-CELL PRECURSOR ALL AND PHARMACOLOGIC INHIBITION ENHANCES ANTI-LEUKEMIA EFFECTS IN VITRO AND VIVO

EHA Library, Hongbo He, 4209098

PH+ ALL CELLS INDUCE ENDOGENOUS PD-L1 UPREGULATION IN BONE MARROW MESENCHYMAL STROMAL CELLS VIA THE CX43‑XBP1‑STING AXIS TO PROMOTE MICROENVIRONMENTAL IMMUNOSUPPRESSION

EHA Library, Chengyan Chai, 4209100

KSR2 IS A NOVEL ONCOGENE IN TAL1 SUBTYPE OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA WITH POTENTIAL CLINICAL AND PROGNOSTIC IMPLICATIONS

EHA Library, Monika Drobna-Sledzinska, 4209101

ENTROPY AND TRANSCRIPTIONAL PLASTICITY CHARACTERIZE CONVERGENT INFLAMMATORY–METABOLIC MACROSTATES IN ACUTE LYMPHOBLASTIC LEUKEMIA

EHA Library, Jairo Jattin-Balcázar, 4209103